199 related articles for article (PubMed ID: 10756536)
1. Loteprednol etabonate: a review of ophthalmic clinical studies.
Howes JF
Pharmazie; 2000 Mar; 55(3):178-83. PubMed ID: 10756536
[TBL] [Abstract][Full Text] [Related]
2. Treatment of ocular inflammatory conditions with loteprednol etabonate.
Pavesio CE; Decory HH
Br J Ophthalmol; 2008 Apr; 92(4):455-9. PubMed ID: 18245274
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
[TBL] [Abstract][Full Text] [Related]
4. Change in intraocular pressure during long-term use of loteprednol etabonate.
Novack GD; Howes J; Crockett RS; Sherwood MB
J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
[TBL] [Abstract][Full Text] [Related]
5. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
Abelson M; Howes J; George M
J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
[TBL] [Abstract][Full Text] [Related]
6. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
Asbell P; Howes J
CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis.
Bartlett JD; Howes JF; Ghormley NR; Amos JF; Laibovitz R; Horwitz B
Curr Eye Res; 1993 Apr; 12(4):313-21. PubMed ID: 8319490
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
Holzer MP; Solomon KD; Sandoval HP; Vroman DT
J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
[TBL] [Abstract][Full Text] [Related]
9. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
[TBL] [Abstract][Full Text] [Related]
10. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
Stewart R; Horwitz B; Howes J; Novack GD; Hart K
J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
Ilyas H; Slonim CB; Braswell GR; Favetta JR; Schulman M
Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
[TBL] [Abstract][Full Text] [Related]
12. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
Friedlaender MH; Howes J
Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
[TBL] [Abstract][Full Text] [Related]
13. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
Dell SJ; Shulman DG; Lowry GM; Howes J
Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
[TBL] [Abstract][Full Text] [Related]
14. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
[TBL] [Abstract][Full Text] [Related]
15. Loteprednol etabonate: comparison with other steroids in two models of intraocular inflammation.
Howes JF; Baru H; Vered M; Neumann R
J Ocul Pharmacol; 1994; 10(1):289-93. PubMed ID: 8207332
[TBL] [Abstract][Full Text] [Related]
16. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
Holland EJ; Djalilian AR; Sanderson JP
Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
[TBL] [Abstract][Full Text] [Related]
18. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
Sheppard JD; Comstock TL; Cavet ME
Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
[TBL] [Abstract][Full Text] [Related]
19. Management of seasonal allergic conjunctivitis: guide to therapy.
Bielory BP; O'Brien TP; Bielory L
Acta Ophthalmol; 2012 Aug; 90(5):399-407. PubMed ID: 22067457
[TBL] [Abstract][Full Text] [Related]
20. Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens.
Comstock TL; Holland EJ
Expert Opin Pharmacother; 2010 Apr; 11(5):843-52. PubMed ID: 20210687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
